SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/24/2023
Locations: Metropolitan Heart and Vascular Institute (MHVI), Coon Rapids, Minnesota +1 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD
Recruiting
The purpose of this study is to evaluate the safety and efficacy of once daily oral inhalation dose of MK-5475 380 µg in participants 40 to 85 years (inclusive) with Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease (PH-COPD). The primary hypothesis of the study is MK-5475, a soluble Guanylate Cyclase (sGC) stimulator is superior to placebo in increasing 6 Minute Walking Distance (6MWD) from baseline at Week 24.
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
11/24/2023
Locations: Mayo Clinic in Rochester, Minnesota ( Site 0131), Rochester, Minnesota
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)
Recruiting
This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in participants with Pulmonary Arterial Hypertension (PAH). This open-label, long-term follow-up (LTFU) study is supported by data from the PULSAR study (Phase 2, NCT03496207) in which treatment with sotatercept resulted in hemodynamic and functional improvements in the study participants, including those receiving maximal PAH therapy with double/triple drug... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/23/2023
Locations: University of Minnesota ( Site 1062), Minneapolis, Minnesota
Conditions: PAH, Pulmonary Arterial Hypertension
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
Recruiting
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
11/23/2023
Locations: University of Minnesota Hospitals ( Site 1062), Minneapolis, Minnesota
Conditions: Hypertension, Pulmonary
A Study of Pulmonary Hypertension Peripheral Limitations
Recruiting
The investigators are doing this research study to compare whole body aerobic training with isolated leg training (with weights) and its impact on effectiveness in symptoms and quality of life in patients with Pulmonary Arterial Hypertension (PAH).
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Pulmonary Arterial Hypertension, Healthy
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
Recruiting
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension (PAH). The Phase 2b part of the study will assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase 2b primary endpoint will be the placebo corrected change in pulmonary vascular resistance (PVR). The Phase 3 primary endpoint will be the... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
11/13/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Pulmonary Arterial Hypertension
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
Recruiting
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3 study with an open-label single-arm extension period to evaluate pharmacokinetics (PK), safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
11/07/2023
Locations: Mayo Clinic - PPDS, Rochester, Minnesota
Conditions: Pulmonary Arterial Hypertension
REDUCED 1 - Renal Denervation Using Ultrasonic Catheter EmitteD Energy Study /
Recruiting
This is a prospective, multicenter, non-randomized, open-label clinical study of the safety and performance of the TIVUS™ System in subjects with uncontrolled stage 2 hypertension in order to assess the safety and effectiveness of the TIVUS™ System when used for renal artery denervation. The study will assess the acute and chronic safety of the procedure as well as the reduction in 24-hour ambulatory mean systolic blood pressure from baseline to 3 months after the procedure.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
11/03/2023
Locations: Minneapolis Heart Institution Foundation, Minneapolis, Minnesota
Conditions: Uncontrolled Stage 2 Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Recruiting
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/03/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
A Study to Evaluate Renal Fibrosis Using MRI Techniques
Recruiting
The purpose of this study is to evaluate whether or not an MRI technique (quantitative magnetization transfer or qMT) in narrowing human kidneys is feasible, reproducible, and predicts recovery.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
10/30/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Hypertension, Renovascular
PedsBP Clinical Decision Support Tool
Recruiting
The goal of the PedsBP CDS research project is to adapt a previously tested web-based clinical decision support tool that appropriately identifies high blood pressure in youth for use in a primarily rural health system and compare approaches to CDS implementation in 45 primary care clinics treating children in 3 upper Midwest states. This project will advance implementation science and address a critical need for youth at risk for cardiovascular disease and with limited access to pediatric subsp... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
10/16/2023
Locations: Essentia Health, Duluth, Minnesota
Conditions: Hypertension
Pulmonary Hypertension in Left Heart Disease
Recruiting
The goal is to compare patients with and without varying severity of pulmonary vascular disease based upon hemodynamic signatures, echocardiographic measures, and lung ultrasound, in tandem with expired gas metabolic testing and blood sampling.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/10/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Pulmonary Hypertension, Pulmonary Vascular Disease, Left Heart Disease